The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

SureCN4085     2-[4-(1,2-diphenylbut-1- enyl)phenoxy]-N,N...

Synonyms: AGN-PC-009DRO, KBioGR_000490, KBioGR_001689, KBioGR_002404, KBioSS_000490, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of tamoxifen


Psychiatry related information on tamoxifen


High impact information on tamoxifen


Chemical compound and disease context of tamoxifen


Biological context of tamoxifen


Anatomical context of tamoxifen


Associations of tamoxifen with other chemical compounds


Gene context of tamoxifen


Analytical, diagnostic and therapeutic context of tamoxifen

  • When chemotherapy was added to tamoxifen in the B-20 trial, there was an increased benefit [36].
  • Trials directly comparing AIs with tamoxifen have, to date, demonstrated superior disease-free-survival with AIs [1].
  • The magnitude of the improvement obtained does not preclude the need for future trials in which patients given tamoxifen could serve as the control group in an evaluation of potentially better therapies [37].
  • Tamoxifen significantly reduced the rate of treatment failure at local and distant sites, tumors in the opposite breast, and the incidence of tumor recurrence after lumpectomy and breast irradiation [37].
  • Analysis of the time until treatment failure for the two treatment groups showed no significant difference (medians: DES, 142 days; tamoxifen, 171 days) [13].


  1. Aromatase inhibitors as adjuvant therapy for postmenopausal patients with early stage breast cancer. Kudachadkar, R., O'Regan, R.M. CA: a cancer journal for clinicians. (2005) [Pubmed]
  2. Breast cancer prevention: a review of current evidence. Vogel, V.G. CA: a cancer journal for clinicians. (2000) [Pubmed]
  3. Treatment of advanced endometrial carcinoma with tamoxifen. Swenerton, K.D., White, G.W., Boyes, D.A. N. Engl. J. Med. (1979) [Pubmed]
  4. Tamoxifen-induced endometrial polyp. Neven, P., De Muylder, X., Van Belle, Y. N. Engl. J. Med. (1997) [Pubmed]
  5. Tamoxifen in malignant melanoma. Nesbit, R.A., Woods, R.L., Tattersall, M.H., Fox, R.M., Forbes, J.F., MacKay, I.R., Goodyear, M. N. Engl. J. Med. (1979) [Pubmed]
  6. Contralateral primary tumors in breast cancer patients in a randomized trial of adjuvant tamoxifen therapy. Rutqvist, L.E., Cedermark, B., Glas, U., Mattsson, A., Skoog, L., Somell, A., Theve, T., Wilking, N., Askergren, J., Hjalmar, M.L. J. Natl. Cancer Inst. (1991) [Pubmed]
  7. Breast cancer care in old age: what we know, don't know, and do. Silliman, R.A., Balducci, L., Goodwin, J.S., Holmes, F.F., Leventhal, E.A. J. Natl. Cancer Inst. (1993) [Pubmed]
  8. Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors. Bober, S.L., Hoke, L.A., Duda, R.B., Regan, M.M., Tung, N.M. J. Clin. Oncol. (2004) [Pubmed]
  9. Effects of tamoxifen adjuvant therapy and a low-fat diet on serum binding proteins and estradiol bioavailability in postmenopausal breast cancer patients. Rose, D.P., Chlebowski, R.T., Connolly, J.M., Jones, L.A., Wynder, E.L. Cancer Res. (1992) [Pubmed]
  10. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Shiau, A.K., Barstad, D., Loria, P.M., Cheng, L., Kushner, P.J., Agard, D.A., Greene, G.L. Cell (1998) [Pubmed]
  11. Delayed severe hypertriglyceridemia from tamoxifen. Kanel, K.T., Wolmark, N., Thompson, P.D. N. Engl. J. Med. (1997) [Pubmed]
  12. Images in clinical medicine. Tamoxifen-induced endometrial polyp. Timmerman, D., Vergote, I. N. Engl. J. Med. (1996) [Pubmed]
  13. Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. Ingle, J.N., Ahmann, D.L., Green, S.J., Edmonson, J.H., Bisel, H.F., Kvols, L.K., Nichols, W.C., Creagan, E.T., Hahn, R.G., Rubin, J., Frytak, S. N. Engl. J. Med. (1981) [Pubmed]
  14. Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. Cocconi, G., Bella, M., Calabresi, F., Tonato, M., Canaletti, R., Boni, C., Buzzi, F., Ceci, G., Corgna, E., Costa, P. N. Engl. J. Med. (1992) [Pubmed]
  15. Exploring the mode-of-action of bioactive compounds by chemical-genetic profiling in yeast. Parsons, A.B., Lopez, A., Givoni, I.E., Williams, D.E., Gray, C.A., Porter, J., Chua, G., Sopko, R., Brost, R.L., Ho, C.H., Wang, J., Ketela, T., Brenner, C., Brill, J.A., Fernandez, G.E., Lorenz, T.C., Payne, G.S., Ishihara, S., Ohya, Y., Andrews, B., Hughes, T.R., Frey, B.J., Graham, T.R., Andersen, R.J., Boone, C. Cell (2006) [Pubmed]
  16. High-affinity anti-oestrogen binding site distinct from the oestrogen receptor. Sutherland, R.L., Murphy, L.C., San Foo, M., Green, M.D., Whybourne, A.M., Krozowski, Z.S. Nature (1980) [Pubmed]
  17. Tamoxifen flare in advanced breast cancer. Plotkin, D., Lechner, J.J., Jung, W.E., Rosen, P.J. JAMA (1978) [Pubmed]
  18. Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta. Hughes, D.E., Dai, A., Tiffee, J.C., Li, H.H., Mundy, G.R., Boyce, B.F. Nat. Med. (1996) [Pubmed]
  19. Differences between oestrogen receptor activation by oestrogen and antioestrogen. Rochefort, H., Borgna, J.L. Nature (1981) [Pubmed]
  20. Cellular and molecular pharmacology of antiestrogen action and resistance. Clarke, R., Leonessa, F., Welch, J.N., Skaar, T.C. Pharmacol. Rev. (2001) [Pubmed]
  21. Tamoxifen: toxicities and drug resistance during the treatment and prevention of breast cancer. Jordan, V.C. Annu. Rev. Pharmacol. Toxicol. (1995) [Pubmed]
  22. Goldenhar's syndrome associated with tamoxifen given to the mother during gestation. Cullins, S.L., Pridjian, G., Sutherland, C.M. JAMA (1994) [Pubmed]
  23. Tamoxifen is a potent "pure" anti-oestrogen in chick oviduct. Sutherland, R., Mester, J., Baulieu, E.E. Nature (1977) [Pubmed]
  24. Tamoxifen elevates transforming growth factor-beta and suppresses diet-induced formation of lipid lesions in mouse aorta. Grainger, D.J., Witchell, C.M., Metcalfe, J.C. Nat. Med. (1995) [Pubmed]
  25. Estrogen-dependent Leydig cell protein recognized by monoclonal antibody to MCF-7 cell line. Ciocca, D.R., Dufau, M.L. Science (1984) [Pubmed]
  26. Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells. Spiotto, M.T., Yu, P., Rowley, D.A., Nishimura, M.I., Meredith, S.C., Gajewski, T.F., Fu, Y.X., Schreiber, H. Immunity (2002) [Pubmed]
  27. New carbon dioxide-independent basal growth medium for culture of diverse tumor and nontumor cells of human and nonhuman origin. Vistica, D.T., Scudiero, D., Skehan, P., Monks, A., Boyd, M.R. J. Natl. Cancer Inst. (1990) [Pubmed]
  28. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. Love, R.R., Mazess, R.B., Barden, H.S., Epstein, S., Newcomb, P.A., Jordan, V.C., Carbone, P.P., DeMets, D.L. N. Engl. J. Med. (1992) [Pubmed]
  29. Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Paech, K., Webb, P., Kuiper, G.G., Nilsson, S., Gustafsson, J., Kushner, P.J., Scanlan, T.S. Science (1997) [Pubmed]
  30. Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth. O'Regan, R.M., Cisneros, A., England, G.M., MacGregor, J.I., Muenzner, H.D., Assikis, V.J., Bilimoria, M.M., Piette, M., Dragan, Y.P., Pitot, H.C., Chatterton, R., Jordan, V.C. J. Natl. Cancer Inst. (1998) [Pubmed]
  31. Triphenylethylenes: a new class of protein kinase C inhibitors. O'Brian, C.A., Liskamp, R.M., Solomon, D.H., Weinstein, I.B. J. Natl. Cancer Inst. (1986) [Pubmed]
  32. Effects of chemopreventive and antitelomerase agents on the spontaneous immortalization of breast epithelial cells. Herbert, B.S., Wright, A.C., Passons, C.M., Wright, W.E., Ali, I.U., Kopelovich, L., Shay, J.W. J. Natl. Cancer Inst. (2001) [Pubmed]
  33. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. King, M.C., Wieand, S., Hale, K., Lee, M., Walsh, T., Owens, K., Tait, J., Ford, L., Dunn, B.K., Costantino, J., Wickerham, L., Wolmark, N., Fisher, B. JAMA (2001) [Pubmed]
  34. Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer. Foekens, J.A., Look, M.P., Peters, H.A., van Putten, W.L., Portengen, H., Klijn, J.G. J. Natl. Cancer Inst. (1995) [Pubmed]
  35. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. Osborne, C.K., Bardou, V., Hopp, T.A., Chamness, G.C., Hilsenbeck, S.G., Fuqua, S.A., Wong, J., Allred, D.C., Clark, G.M., Schiff, R. J. Natl. Cancer Inst. (2003) [Pubmed]
  36. Highlights from recent National Surgical Adjuvant Breast and Bowel Project studies in the treatment and prevention of breast cancer. Fisher, B. CA: a cancer journal for clinicians. (1999) [Pubmed]
  37. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. Fisher, B., Costantino, J., Redmond, C., Poisson, R., Bowman, D., Couture, J., Dimitrov, N.V., Wolmark, N., Wickerham, D.L., Fisher, E.R. N. Engl. J. Med. (1989) [Pubmed]
WikiGenes - Universities